Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity Non-inferiority Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 Years Old vs Healthy Population Aged 18 Years Old and Above

NCT04917523 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.

NCT NCT04917523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04917523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity Non-inferiority Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 Years Old vs Healthy Population Aged 18 Years Old and Above
Lead sponsor
China National Biotec Group Company Limited
Phase
Phase 3
Overall status
Completed
Start date
July 2, 2021
Completion date
April 29, 2022
Enrollment
1,800 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 pneumonia